Financial Performance - Revenue for the year ended December 31, 2022, was RMB 4,329,075 thousand, representing a 17.7% increase from RMB 3,678,690 thousand in 2021[1] - Gross profit for the same period was RMB 1,449,670 thousand, up 24.7% from RMB 1,162,311 thousand in 2021[1] - The net loss for the year was RMB 2,842,275 thousand, a 77.8% increase compared to RMB 1,598,974 thousand in 2021[1] - Adjusted net loss (non-IFRS measure) improved to RMB 128,698 thousand, a 60.9% decrease from RMB 329,525 thousand in 2021[1] - Total revenue for the year ended December 31, 2022, was RMB 4,329,075,000, an increase of 17.7% from RMB 3,678,690,000 in 2021[12] - Revenue from pharmaceutical and healthcare business reached RMB 4,201,618,000, up from RMB 3,561,336,000 in the previous year, reflecting a growth of 18.1%[12] - Total revenue for the year ended December 31, 2022, increased to RMB 4,329.1 million, a year-on-year growth of 17.7% from RMB 3,678.7 million in 2021[30] - Revenue from pharmaceutical and healthcare business rose by 18.0% to RMB 4,201.6 million from RMB 3,561.3 million in 2021[44] Assets and Liabilities - Total assets as of December 31, 2022, amounted to RMB 3,297,475 thousand, compared to RMB 2,946,159 thousand in 2021[7] - Cash and cash equivalents were RMB 1,210,949 thousand, down from RMB 1,552,994 thousand in 2021[6] - Total liabilities decreased to RMB 1,098,279 thousand from RMB 5,535,988 thousand in 2021[7] - Non-current assets totaled RMB 769,888 thousand, an increase from RMB 678,466 thousand in 2021[5] - The company’s equity attributable to owners was RMB 2,185,658 thousand, down from RMB 2,612,247 thousand in 2021[5] - Trade receivables increased to RMB 106,125,000 as of December 31, 2022, up from RMB 91,351,000 in 2021, with an expected credit loss provision of RMB 563,000[21] - Total liabilities increased to RMB 772,817,000 as of December 31, 2022, compared to RMB 586,651,000 in 2021, reflecting a significant rise in trade payables[22] Operational Highlights - The company reported a significant increase in inventory, rising to RMB 607,950 thousand from RMB 434,022 thousand in 2021[6] - Employee benefits expenses totaled RMB 619,446,000, a decrease of 21.5% compared to RMB 789,134,000 in 2021[13] - Interest income from bank deposits increased significantly to RMB 16,730,000 from RMB 3,781,000 in 2021, marking a growth of 341.5%[15] - The company reported a net foreign exchange gain of RMB 14,369,000 for the year, compared to a gain of RMB 11,922,000 in 2021[14] - The total amount of government subsidies received was RMB 7,678,000, slightly down from RMB 8,390,000 in the previous year[15] - The company accumulated 37.5 million registered users through its online platform, with total orders amounting to 61.7 million during the reporting period[33] - Revenue from the online direct sales channel was RMB 3,091.0 million, representing a 19.6% increase from RMB 2,583.6 million in 2021[33] - Offline retail revenue amounted to RMB 674.0 million, reflecting an 18.5% increase from RMB 568.8 million in 2021[35] Strategic Initiatives - The company successfully entered the Hong Kong capital market in 2022, marking a new starting point for digital health service innovation[26] - The company established an ESG management system in 2022 to enhance product safety and information security, contributing value to employees, users, partners, and the public[28] - In 2023, the company aims to enhance the accessibility and convenience of medical and pharmaceutical services through its digital supply chain and smart pharmacy network in 19 core cities[28] - The company plans to increase the proportion of pharmacies included in medical insurance and strengthen the FSC pharmaceutical alliance to improve service capabilities and user engagement[28] - A new five-year plan will be initiated to promote technological and business innovation, focusing on the digital empowerment of physical pharmacies[28] - The company will continue to develop a service ecosystem around "medicine, testing, pharmaceuticals, and insurance" to drive digital transformation in the industry[28] - The company aims to enhance its competitive advantage and market share in the cities where it operates, creating long-term value for users and shareholders[28] - The company emphasizes its commitment to user-centered services and aims to lead in home health services[28] Expenses and Losses - Fulfillment expenses increased by 7.7% to RMB 444.2 million for the year ended December 31, 2022, while the percentage of fulfillment expenses to revenue decreased from 11.2% to 10.3%[47] - Sales and marketing expenses rose by 8.8% to RMB 908.2 million for the year ended December 31, 2022, with the percentage of these expenses to revenue decreasing from 22.7% to 21.0%[48] - R&D expenses decreased by 7.5% to RMB 89.0 million for the year ended December 31, 2022, with the percentage of R&D expenses to revenue declining from 2.6% to 2.1%[49] - General and administrative expenses decreased by 30.5% to RMB 334.5 million for the year ended December 31, 2022, with the percentage of these expenses to revenue dropping from 13.1% to 7.7%[50] - Fair value losses on financial liabilities increased by 174.6% to RMB 2,504.5 million for the year ended December 31, 2022, primarily due to increased fair value losses on preferred shares[51] - Net loss increased by 77.8% to RMB 2,842.3 million for the year ended December 31, 2022, compared to RMB 1,599.0 million for the year ended December 31, 2021[55] - Adjusted net loss for the year ended December 31, 2022, was RMB 128.7 million, with an adjusted net loss margin of 3.0%, compared to an adjusted net loss of RMB 329.5 million and a margin of 9.0% for the year ended December 31, 2021[56] Cash Flow and Capital Expenditure - The net cash used in operating activities for the year ended December 31, 2022, was RMB 237.9 million, compared to RMB 295.5 million in the previous year, primarily due to a pre-tax loss of RMB 2,832.1 million[58] - The net cash used in investing activities for the year ended December 31, 2022, was RMB 353.4 million, mainly due to the purchase of financial assets at fair value through profit or loss amounting to RMB 6,427.6 million[59] - The net cash generated from financing activities for the year ended December 31, 2022, was RMB 232.9 million, primarily from the net proceeds of RMB 325.8 million from the global offering of ordinary shares[60] - The company's capital expenditure for the year ended December 31, 2022, was RMB 30.0 million, slightly up from RMB 29.3 million in 2021[61] - As of December 31, 2022, the company had no bank borrowings and therefore no capital debt ratio[61] Governance and Reporting - The company has adhered to the corporate governance code since its listing on September 14, 2022, with a commitment to high standards of governance[69] - The audit committee, consisting of three independent non-executive directors, has reviewed the audited financial statements for the year ending December 31, 2022[74] - The annual report for the year ending December 31, 2022, will be published on the Hong Kong Stock Exchange and the company's website[75]
叮当健康(09886) - 2022 - 年度业绩